Simulations Plus (NASDAQ:SLP): Promising Potential in Biotech Software

Simulations Plus (SLP) DILIsym Software Licenses Renewed by FDA

Simulations Plus (SLP) Q2 Earnings & Revenues Beat Estimates

Simulations Plus Inc (SLP) Aligns with EPS Projections and Maintains Full-Year Guidance

Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates

Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates

Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results

Simulations Plus (SLP) to Report Q2 Earnings: What's in Store?

Simulations Plus (SLP) to Report Q2 Earnings: What's in Store?

Craig-Hallum Remains a Buy on Simulations Plus (SLP)

Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date

Adobe Systems (ADBE) Tops Q1 Earnings and Revenue Estimates

Investing in Simulations Plus (NASDAQ:SLP) five years ago would have delivered you a 110% gain

Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

Director and 10% Owner Walter Woltosz Sells 20,000 Shares of Simulations Plus Inc (SLP)

Simulations Plus and the University of Bath Awarded New FDA Grant